Akeso Biopharma, Inc.
Records under this name other than the patents Akeso Biopharma, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 17 patents it holds.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| 17/272,121 | Methods for Treating a Tumor Using an ANTI-VEGFA/PD-1 Bifunctional Antibody Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/419,109 | Antibody Against Human IL-4RA and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/630,467 | ANTI-CTLA4-ANTI-PD-1 Bispecific Antibody and Uses Thereof now held by Akeso Pharmaceuticals, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/630,477 | ANTI-PD-1 Antibody and Medical Use Thereof now held by CTTQ-Akeso (Shanghai) Biomed. Tech. Co., Ltd. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 17/779,425 | ANTI-PD-1-ANTI-VEGFA Bispecific Antibody, Pharmaceutical Composition and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/021,167 | ANTI-CD73 Antibody and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/024,471 | ANTI-CD47 Monoclonal Antibody and Use Thereof held by Akeso Biopharma, Inc. and Akeso Pharmaceuticals, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/024,478 | Pharmaceutical Combination Containing ANTI-PD-1-ANTI-VEGFA Bispecific Antibody, and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/250,010 | ANTI-CD73 Antibody and Use Thereof held by Akeso Biopharma, Inc. and Akeso Pharmaceuticals, Inc. Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. | |
| 18/264,138 | Pharmaceutical Composition Comprising Anti-Tigit Antibody and ANTI-PD-1/ANTI-VEGFA Bispecific Antibody, and Use Thereof Pending Term is not computable until grant, so no date is shown and no estimate is implied. | Pending | Term is not computable until grant, so no date is shown and no estimate is implied. |